• Updates Archive

    06.09.14 - ACCRF Update

    A review of the ACCRF Scientific Forum at the Salk Institute, recent clinical trial developments, NIH grant announcements and patient events.

    More »

    12.15.13 - ACCRF Year-End Letter

    A blend of annual accomplishments, patient education resources and clinical trial developments.

    More »

    10.18.13 - Update for Researchers

    A review of recent developments, including The Landscape of ACC Research, orphan drug designation for Dovitinib, the International MYB Conference, new MYB antibodies and NIDCR research on salivary gland tumors.

    More »

    06.18.13 - More on “Quiet” Genomes

    Yet another seminal study of ACC genomics reveals “quiet” genomes with relatively few molecular alterations in most tumors. The implication is that less complex tumors may be more vulnerable to the correct targeted drugs.

    More »

    05.31.13 - Genomic Findings, Clinical Trials & Patient Activities

    The past few months have seen a flurry of significant research findings. A major scholarly article depicts the landscape of ACC genomics and four reports from ACC clinical trials point to encouraging results. Meanwhile, patients gathered, supported each other and raised funds for more research.

    More »

    12.20.12 - ACCRF Year End Letter

    Highlights from a remarkable year include a third Dovitinib clinical trial, $8 million in NIH grants and a revamped website.

    More »

    09.20.12 - 3rd Workshop on Salivary Gland Tumors

    The re-invigoration of the field of salivary gland tumor research over the past 6 years has been a very welcome development for ACC patients. A recent NIH workshop attracted many new investigators and highlighted many active collaborations.

    More »

    02.03.12 - Dovitinib Study Opens at the University of Virginia

    The University of Virginia has begun screening ACC patients with progressive disease for a new clinical trial. Supported by Novartis Pharmaceuticals, the Phase II study will enroll 10 patients to determine the efficacy and safety of the oral drug Dovitinib, an inhibitor of FGFR, VEGFR and PDGFR.

    More »

    01.09.12 - RFAs for Salivary Gland Tumor Research

    The National Institute of Dental and Craniofacial Research (NIDCR) posted two Requests for Applications (RFAs) seeking grant proposals to enhance basic and translational research on salivary gland tumors (SGTs). This anticipated commitment of approximately $8 million over the next four years underscores the continuing strong leadership of NIDCR in this under-studied field.

    More »

    12.21.11 - ACCRF Year End Letter (2011)

    Your support made 2011 a banner year! And together we can do even more in 2012! Your generosity and the deep commitment of our affiliated researchers have allowed us to reach some crucial milestones and chart the path forward for more successes.